10x Genomics (TXG) Cash from Financing Activities (2018 - 2026)

10x Genomics (TXG) has 9 years of Cash from Financing Activities data on file, last reported at -$8.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 2094.55% year-over-year to -$8.4 million; the trailing twelve-month figure through Mar 2026 stood at -$2.0 million (down 120.99% YoY), and the FY2025 full-year result was $6.8 million, down 37.67% from the prior year.
• Cash from Financing Activities declined to -$8.4 million in Q1 2026, from $2.2 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $7.1 million in Q2 2023 to a low of -$8.4 million in Q1 2026.
• A 5-year average of $2.3 million and a median of $2.4 million in 2022 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities jumped 295.51% in 2025 and tumbled 2094.55% in 2026, its largest moves.
• Tracing TXG's Cash from Financing Activities over 5 years: stood at $5.0 million in 2022, then advanced by 12.24% to $5.6 million in 2023, then slipped by 19.53% to $4.5 million in 2024, then slumped by 50.37% to $2.2 million in 2025, then slumped by 475.42% to -$8.4 million in 2026.
• Business Quant data shows TXG's Cash from Financing Activities at -$8.4 million in Q1 2026, $2.2 million in Q4 2025, and $617000.0 in Q3 2025.